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immune activation and modulates 
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The use/misuse of antibiotics leads to pathological features referring to antibiotic-induced intestinal 
injury (AIJ), a clinical issue that plays a prominent role in the development of severe digestive 
disturbances. AIJ is characterized by loss of intestinal architecture and function, dysbiosis and bacterial 
translocation into the liver, triggering hepatic inflammation. This study aimed at determining the 
beneficial effect of N-(1-carbamoyl-2-phenylethyl) butyramide (FBA), a butyrate releasing compound, 
in ceftriaxone-induced intestinal injury. To this purpose, mice receiving ceftriaxone (8 g∙kg−1/die, per os) 
for five days, were treated with FBA (212,5 mg∙kg−1/die, per os) for five or fifteen days. FBA modulated 
key players of innate immunity in antibiotic-injured gut tissues, reducing inflammatory process and 
improving the anti-inflammatory and resolving pattern. FBA also improved colonic architecture and 
intestinal integrity. Interestingly, we also observed a remodeling of gut microbiota composition related 
to an increase of metabolic pathways related to lactate and butyrate production. At mechanistic 
level, FBA induced histone acetylation and increased the expression of GPR43 and monocarboxylate 
transporter 1 in colon. Our data clearly demonstrated that FBA has multiple converging mechanisms in 
limiting intestinal and hepatic alterations to counteract AIJ.
Antibiotics are one of the most used drug classes to manage infectious disorders. Although the discovery of anti-
biotics represents the breakthrough in medicine history, over the years, the medical overuse of broad spectrum 
agents has dramatically increased1,2 as well as the exposure to low levels of antibiotics contained in food and 
water3. Indeed, these drugs can induce several gastrointestinal (GI) adverse events, commonly ascribed to their 
ability of altering gut microbiota composition and diversity, the so-called dysbiosis. Epidemiological studies4,5 
and data on antibiotic-induced alteration in gut microbiota indicate an increased risk of developing inflamma-
tory bowel diseases and post-infective irritable bowel syndrome, secondary to dysbiosis and bacterial transloca-
tion6,7. Although there is great inter-individual variation in the composition of gut microbiota, a set of specified 
functions are shared among individuals referred to the activity of common core gut microbiome8, suggesting the 
importance of a defined consortium of gut bacteria and its related functions in maintaining host homeostasis. 
The mechanisms through which intestinal dysbiosis induced by antimicrobial drugs can trigger alterations at 
digestive and extra-digestive sites are poorly understood, and, most importantly, there is a lack of effective and 
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specific therapeutic interventions for their management. AIJ is characterized by modifications of gut microbiota 
and intestinal architecture, with a shift from eubiosis to dysbiosis, leading to loss of beneficial metabolic activities 
of the colonic microbiota, i.e. extraction of nutrients, digestion of polysaccharides, energy metabolism, regula-
tion of fat storage, synthesis of vitamins and short-chain fatty acids (SCFAs), essentials for gut functionality9,10. 
Among SCFAs, butyrate plays a pivotal role as nutrient for the colonic epithelium, influencing the composition 
of gut microbiota11,12 and modulating directly or indirectly immune and inflammatory response13,14. Butyrate 
carries out its activities through its interaction with G-protein coupled receptors, GCPRs, namely GPR41 and 
GPR43, and via inhibition of histone deacetylase (HDAC), modulating gene expression through an epigenetic 
mechanism15. Butyrate-induced GPR and downstream mitogen-activated protein kinase signaling activation, 
occurring through GPR41 and 43, regulates inflammatory pathways involved in gut health16,17. Moreover, activa-
tion of GCPRs by butyrate in the gut also produces the endocrine hormones glucagon-like peptide 1 (GLP-1) and 
peptide YY (PYY), involved in the control of glucose and lipid metabolism18,19. However, since the intracellular 
signaling pathways of butyrate are pleiotropic, the physiologic function and pharmacologic effects of butyrate are 
multivariate, depending upon tissue type, dosage and time effects.
Recently, we demonstrated that a butyrate derivative, N-(1-carbamoyl-2-phenylethyl) butyramide (FBA) 
improved inflammatory colitis induced by dextran sodium sulfate20. Indeed, FBA showed a pharmacological 
profile similar to that of butyrate, also in reducing steatosis13 and insulin resistance21 in high fat diet fed animals. 
Actually, the unpleasant taste and odour make extremely difficult the oral administration of butyrate, particularly 
in poorly compliant children. The aim of this study was to evaluate the protective and anti-inflammatory effect 
of FBA, owing better palatability and compliance than the parental drug, in colon tissue after AIJ by ceftriaxone 
exposure. We studied its capability in reducing gut inflammation, analyzing colonic cytokines, proteins involved 
in epithelium repair and integrity, colon responsiveness thorough TLRs expression, and liver innate response 
and in modulating gut microbiota composition, trying to obtain an overall picture on the early and late phases of 
antibiotic-induced injury and their pharmacological control by FBA. Finally, we tried to shed light on the mecha-
nisms underlying FBA treatment, addressing the expression of proteins related to butyrate effects.
Results
FBA reduces colon inflammation and tissue damage. FBA modulated pro- and anti-inflammatory 
patterns in colon tissue. The mRNA expression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, IFN-γ) and 
enzyme (COX-2) was widely enhanced in the colon of AIJ mice (Fig. 1A–E), while that of the anti-inflammatory 
cytokine IL-10 was reduced (Fig. 1F). FBA not only counteracted inflammation and improved anti-inflammatory 
response, but also normalized the expression of the resolvin annexin (Anx) A1 (Fig. 1G).
Colon sections from AIJ 15 mice, stained with H&E, showed hyperplastic glands and apoptotic bodies 
(Fig. 2A, see arrows), with cell shrinkage, condensed cytoplasm and pyknotic and fragmented nuclei, com-
pared to CON sections. Furthermore, the administration of ceftriaxone induced a reduced mucus thickness 
and an increased number of apoptotic bodies in colon sections (see Table 1). FBA treatment in injured animals 
Figure 1. FBA reduces colon inflammation after 5 or 15 days of treatment. (A–G) Transcriptional levels of Il1b, 
Il6, Tnfa, Ifng, Ptgs2, Il10, Anxa1 were evaluated in colonic tissues (n = 6). Real-Time PCR data are presented as 
mean ± S.E.M. All results were considered statistically significant at P < 0.05. Labeled means without a common 
letter differ, P < 0.05.
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normalized mucosa structure, showing a regular brush border and straight and unbranched crypts with lined 
largely goblet cells similar to those of CON (Fig. 2A). The improvement of mucus layer can be attributed to 
FBA capability in increasing the transcription of acute phase of protective trefoil factor 3 (TFF3) and mucin 2 
(Fig. 2B,C).
In the early phase of antibiotic-induced damage, AIJ 5 mice showed a significant reduction of AQP9, a water 
channel mainly located in the intestinal tract managing fecal water content22, and of occludin (OCLN), a crucial 
tight junction (TJ) for the maintenance of intestinal integrity (Fig. 2D,E).
FBA reduces gut and liver inflammation, downregulating TLR4 and inhibiting NFκB activa-
tion. As shown in Fig. 3A,B, after 5 d, antibiotic treatment increases TLR4 protein and Myeloid differen-
tiation primary response (Myd) 88 mRNA expression in colon. FBA significantly inhibited these effects, and 
blocked the activation of NFκB pathway induced by ceftriaxone, preventing the translocation of NFκB p65 
subunit in nucleus and consistently increasing IκB-α expression in cytosol (Fig. 3C,D). Antibiotic treatment 
also reduced TLR2 transcription, and a not significant increasing trend of its restoration was shown by FBA 
treatment (Fig. 3E). Interestingly, a similar profile of TLR4/Myd88 expression was observed in liver (Fig. 3F,G), 
probably due to a greater hepatic exposure to TLR ligands (i.e. Pathogen Associated Molecular Patterns, PAMPs, 
microbe-associated molecular patterns, MAMPs, and Damage-associated molecular patterns, DAMPs) deriving 
Figure 2. Effects of FBA on colonic morphology and integrity. (A) Distal colons from CON, AIJ 15, and AIJ 
15 + FBA were stained with H&E. Scale bar: 100 µm (10x), and 50 (20x). Black arrows indicate apoptotic bodies. 
Representative pictures of all sections are shown. (B,C) The transcription of trefoil factor 3 (Tff3) and mucin 
2 (Muc2) was also evaluated in colonic tissues of CON, AIJ 5 and AIJ 5 + FBA animals. (D) Representative 
immunoblot of AQP9 is shown (n = 6). The densitometric analysis of all determinations is also reported. All 
data are expressed as mean ± S.E.M. Equal loading was confirmed by β-actin. (E) mRNA expression of OCLN 
in colon tissue is also shown (n = 6). All results were considered statistically significant at P < 0.05. Labeled 
means without a common letter differ, P < 0.05.
Histological parameters CON AIJ 15 AIJ 15 + FBA
Glandular hyperplasia 0-1 mitosis/HPF 1-2 mitosis/HPF 1-2 mitosis/HPF
Apoptosis 0-1/HPF 2-3/HPF 1-2/HPF
Mucus thickness 100 82,6 110,9
Table 1. Histological scores of CON, AIJ and AIJ + FBA colon tissues at 15 day. Score for glandular hyperplasia 
and apoptosis: 0 = none, 1 = mild, 2 = moderate, 3 = severe. Score for mucus thickness (% vs control).
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from the intestine. Liver inflammation was confirmed by the increase of mRNA transcription of inflammasome, 
NACHT, LRR and PYD domains-containing protein (NLRP) 3 (Fig. 3H) and limited by FBA treatment.
Taxonomy-based analysis of microbiota changes. A subset of mice from each group was analyzed for 
gut microbiota by Illumina MiSeq technology. After processing, a total 1,514,762 valid reads were identified with 
an average of 63,115.08 ± 32,899.69 reads/sample and a sequencing depth of 23,422 reads/sample, representing 
the Good’s coverage of 99% or above for all samples (Table S1). All sequences were classified in 3,805 OTUs rep-
resenting 18 phyla, 338 genera and 754 diverse species.
For alpha diversity analysis, Observed Species was significantly lower at AIJ 5 and AIJ 15 compared to CON 
groups, indicating a drastic decline in bacterial richness after antibiotic administration; upon FBA treatment at 5 
and 15 days modification of species richness was observed in comparison with AIJ mice (Table 2). Phylogenetic 
distances of bacterial species among groups were measured by unweighted UniFrac analysis and reported in the 
principal coordinate analysis (PCoA) plot (Fig. 4A). In the plot, all controls (a), 5 day FBA treatment (b), and 
both 15 day AIJ groups in absence (c) or presence (d) of FBA showed non-overlapping clustering, indicating dif-
ferences in microbiota structure among groups. Notably, at 15 days after AIJ, remodeling of microbiota structure 
was significantly different (R = 1; p = 0.02) in absence or presence of FBA (Fig. 4A).
Figure 3. Effect of FBA on immunological and inflammatory mediators: gut-liver axis. (A–D) TLR4, Myd88, 
NFkB and Ikbα were determined in colonic tissues (n = 6). (E) mRNA expression of TLR2 in colon tissue is also 
shown. Furthermore, (F–H) the activity of FBA on TLR4, Myd88 and Nlrp3 was evaluated in liver (n = 6). For 
representative western blots, equal loading was confirmed by β-actin, lamin A or GAPDH. The densitometric 
analysis quantification of all determinations is also reported. All data are expressed as mean ± S.E.M. All results 
were considered statistically significant at P < 0.05. Labeled means without a common letter differ, P < 0.05.
5Scientific RepoRts |          (2019) 9:4832  | https://doi.org/10.1038/s41598-019-41295-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
Comparison of gut microbiota in the different groups was carried out at phylum and genus levels (Table S2 
and Fig. 4B). Reduction of Bacteroidetes and Firmicutes phyla and increase of Cyanobacteria and Proteobacteria 
were observed in AIJ 5 groups both in absence or presence of FBA (Table S2). After 15 days from antibiotic 
administration, the relative abundance of the described phyla was almost completely resumed to initial val-
ues; notably in FBA treated group the ratio of Bacteroidetes to Firmicutes was markedly shifted to Firmicutes 
(Fig. 4B). In particular, Firmicutes significantly increased in AIJ 15 + FBA compared to AIJ 15 (90.0% ± 5.80% 
vs 43.28% ± 7.10%, respectively), while Bacteroidetes significantly decreased (0.19% ± 0.06% vs 39.83% ± 7.43% 
in AIJ 15 + FBA and AIJ 15, respectively). Several genera differed significantly in abundance among groups 
(Fig. 4C). In particular, among genera with a mean relative abundance >1% our analysis showed a reduction 
of U.g. of Rikenellaceae and S24-7 (Bacteroidetes) and of U.g. of Clostridiales and Lachnospiraceae (Firmicutes) 
and an increase of U.g. Streptophyta (Cyanobacteria) and Acinetobacter (Proteobacteria) in AIJ 5 groups both 
in absence or presence of FBA (Fig. 4C). After 15 days both in absence or presence of FBA, U.g. Streptophyta, 
U.g. Lachnospiraceae and Acinetobacter levels were reestablished, this did not occur for U.g. of Rikenellaceae and 
U.g. of Clostridiales. Among genera, FBA at 15 days increased of Firmicutes/Bacteroidetes ratio, mainly corre-
lated to a decrease of U.g. S24-7 (Barnesiella intestinihominis, phylum Bacteroidetes) and increase of Enterococcus 
(E. faecium and U.s. of Enterococcus, phylum Firmicutes) and Clostridium (C. butyricum and C. quinii, phylum 
Firmicutes) levels (Fig. 4C and Table 2). All bacterial species belonging to key genera are reported in Table S3, 
discriminating CON, AIJ and AIJ + FBA groups at 5 and 15 days.
To translate microbiota shift observed upon FBA administration into specific metabolic features of the cor-
responding microbiome, Phylogenetic Investigation of Communities by Reconstitution of Unobserved State 
(PICRUSt) analysis was applied. Considering butyrate producer assortment in clostridial species among groups, 
we focused on KEGG orthologs involved in butyrate metabolism (Table S3). The analysis showed significant 
enrichment of a key enzyme involved in butyrate metabolism (K01034/5) in AIJ 15 + FBA group compared to 
respective AIJ and CON groups. Furthermore, in AIJ 15, FBA administration induced a significant enrichment 
of K00016 function (L-lactate dehydrogenase), the enzyme catalyzing the interconversion of pyruvate and lactate 
(Table S3). Pearson correlation coefficient was used to associate PICRUSt data with identified key species discrim-
inating CON, AIJ and AIJ + FBA microbial communities at 5 and 15 days (Fig. 5). Interestingly, data obtained 
showed a marked positive correlation among species belonging to genus Enterococcus, C. butyricum and C. quinii 
and butyryl-CoA:acetate CoA-transferase (K01034/5) and L-lactate dehydrogenase (K00016).
Genus Species CON 5 AIJ 5 AIJ 5 + FBA CON 15 AIJ 15 AIJ 15 + FBA
U.g of Rikenellaceae
Alistipes finegoldii 1E-3 ± 1E-3a 0a 0a 1.93 ± 0.99b 1E-3 ± 1E-3a 2E-3 ± 1E-3a
Alistipes massiliensis 1.36 ± 0.42a 0.01 ± 0.01a 0.03 ± 0.01a 4.17 ± 0.78b 4E-3 ± 2E-3a 5E-3 ± 3E-3a
Alistipes putredinis 2.4 ± 1.45a 0.01 ± 0.01b 0.04 ± 0.01b 2.36 ± 0.66a 1E-3 ± 1E-3b 2E-3 ± 1E-3b
U.s. of Alistipes 0.53 ± 0.32a 0.01 ± 0.01a 2E-3 ± 1E-3a 1.93 ± 0.84b 0a 0a
U.g of S24-7 Barnesiella intestinihominis 48.62 ± 8.15a 0.85 ± 0.1b 1.37 ± 0.55b 40.3 ± 2.15c 39.81 ± 7.42c 0.16 ± 0.06b
U.g. of Streptophyta Unclassified 0.01 ± 0.01a 54.89 ± 10.48b 51.35 ± 12.49b 2E-3 ± 1E-3a 0.02 ± 3E-3a 0.08 ± 0.01a
Enterococcus
U.s. of Enterococcus 0a 0a 1E-3 ± 1E-3a 1E-3 ± 1E-3a 0.07 ± 0.02a 9.36 ± 5.03b
Enterococcus faecium 6E-3 ± 6E-3a 0a 6E-3 ± 4E-3a 1E-3 ± 1E-3a 0.06 ± 0.01a 6.66 ± 3.75b
U.g. of Clostridiales
Acetatifactor muris 0.81 ± 0.5a 0.02 ± 0.01bc 0.05 ± 0.05abc 0.33 ± 0.01abc 0.01 ± 3E-3bc 1E-3 ± 1E-3bc
Alkaliphilus crotonatoxidans 1.12 ± 0.33a 0b 0.04 ± 0.02b 0.43 ± 0.02ab 0b 1E-3 ± 1E-3b
Unclassified 3.56 ± 3.08a 0.02 ± 0.02b 0.38 ± 0.14b 6.28 ± 1.7c 0.07 ± 0.03b 0.03 ± 0.01b
U.s. of Clostridium 7.04 ± 2.57a 6E-3 ± 1E-3b 0.02 ± 0.02b 4.38 ± 0.12c 0.92 ± 0.45d 0.16 ± 0.06b
Anaerosporobacter mobilis 0.03 ± 0.03a 0a 0a 0.89 ± 0.43b 4E-3 ± 4E-3a 0a
Clostridium aldenense 2.53 ± 0.99a 0.11 ± 0.08b 0.01 ± 0.01b 1.45 ± 0.53c 0.13 ± 0.01b 1E-3 ± 1E-3b
Clostridium aminovalericum 1.01 ± 0.98a 1E-3 ± 1E-3b 0b 0.13 ± 0.041b 0.01 ± 4E-3b 0b
Clostridium asparagiforme 1.77 ± 0.56a 0.09 ± 0.04b 0.05 ± 0.02b 0.81 ± 0.03c 1.93 ± 1.04a 0.01 ± 4E-3b
Clostridium celerecrescens 2.84 ± 2.54a 1E-3 ± 1E-3b 0.01 ± 0.01b 0.21 ± 0.07b 0.25 ± 0.13b 1E-3 ± 1E-3b
Clostridium lactatifermentans 0.04 ± 0.01a 0.01 ± 0.01a 0a 0.1 ± 0.01a 1.01 ± 0.24b 0.14 ± 0.07a
Clostridium saccharolyticum 1.84 ± 0.99a 2E-3 ± 2E-3b 5E-3 ± 3E-3b 0.64 ± 0.09bc 0.92 ± 0.53c 0b
Clostridium
Clostridium butyricum 0a 0a 0a 0.01 ± 4E-3a 12.75 ± 6.11b 38.95 ± 3.5c
Clostridium quinii 0a 0a 0a 0a 0.04 ± 0.02a 5.25 ± 2.84b
U.g. of 
Lachnospiraceae
Clostridium aldenense 0.02 ± 0.01a 0a 1E-3 ± 1E-3a 6E-3 ± 3E-3a 8.83 ± 4.99b 3E-3 ± 2E-3a
Clostridium clostridioforme 3.37 ± 2.74a 0b 0b 0.93 ± 0.53b 6E-3 ± 3E-3b 0.01 ± 0.01b
Clostridium hathewayi 7E-3 ± 4E-3a 0a 1E-3 ± 1E-3a 2E-3 ± 1E-3a 0.3 ± 0.1a 5.97 ± 3.41b
Acinetobacter Unclassified 0a 4.1 ± 1.88a 9.17 ± 8.46b 1E-3 ± 1E-3a 1E-3 ± 1E-3a 0.01 ± 0.01a
Table 2. Species classification of key genera discriminating CON, AIJ and AIJ + FBA microbial communities 
at 5 and 15 days. Reported is mean relative abundance ± S.E.M. of bacterial species according to SPINGO 
classification with significant differences (P < 0.05) among groups as assessed by one-way ANOVA followed by 
Tukey’s multiple comparison post-hoc test (different letters indicated significant differences among groups).
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The effects of FBA involve monocarboxylate transporter (MCT) 1, GPR43 and inhibition of 
HDAC. FBA, as butyrate-releasing derivative, epigenetically regulates gene expression, inhibiting the mRNA 
expression of Hdac9 and increasing the acetylation of nuclear histone H3 in colon, both altered by ceftriaxone 
challenge (Fig. 6A,B). Previous data showed a reduction of the solute transporter of butyrate MCT1 expression 
and function in intestinal inflammation23. FBA exerts its beneficial effects, increasing GPR43 protein and restor-
ing solute carrier family 16 member (Slc16a) 1 transcription, partially altered in AIJ 5 (Fig. 6C,D).
Figure 4. Taxonomy-based analysis of microbiota changes upon AIJ and FBA treatment at 5 and 15 days.  
(A) PCoA plot based on unweighted UniFrac distances of CON, AIJ and AIJ + FBA microbial communities at 
5 and 15 days (23,422 sequences/sample). Analysis of similarity (ANOSIM) with 999 permutations was used to 
detect the statistical significant differences in microbial community composition among groups; on the right 
of the plot are reported both R statistics and p-values. (B) Ratio of Firmicutes and Bacteroidetes abundance in 
CON, AIJ and AIJ + FBA microbial communities at 5 and 15 days. (C) Percentage distribution of the bacterial 
genera with a mean relative abundance > 1% in at least one of the 6 groups found to be significantly different 
among CON, AIJ and AIJ + FBA microbial communities at 5 and 15 days. Variations in ratio and genera relative 
abundances among groups were assessed by one-way ANOVA followed by Tukey’s multiple comparison post-
hoc test (different letters indicated significant differences among groups).
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Figure 5. Heatmap showing the Pearson’s correlation between key functions counts (x-axis) and key species 
discriminating CON, AIJ and AIJ + FBA microbial communities at 5 and 15 days (y-axis). Blue or red colors 
designate the positive or negative correlations, respectively. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 6. Mechanisms of anti-inflammatory activity mediated by FBA. (A,B) The butyrate derivative 
compound decreased transcriptional levels of Hdac9 and enhanced histone H3 acetylation (n = 6). 
Furthermore, (C,D) FBA increased protein level of butyrate receptor, GPR43 and mRNA expression of MCT1 
(n = 6). For representative western blots, equal loading was confirmed by H3 and GAPDH. The densitometric 
analysis quantification of all determinations is also reported. All data are expressed as mean ± S.E.M. All results 
were considered statistically significant at P < 0.05. Labeled means without a common letter differ, P < 0.05.
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Discussion
In this study, we demonstrated the efficacy of FBA, a butyrate-releasing compound, in limiting intestinal injury 
induced by oral administration of ceftriaxone and its capability in remodeling gut microbiota. Here, we provide a 
comprehensive picture of gut perturbations in terms of serum (see Fig. S1) and colon inflammation, liver altera-
tion and microbial dysbiosis and the modulating effect of FBA on all these pathological features consistently asso-
ciated to antibiotic exposure. Many studies mainly focused on antibiotic impact on gut microbiota composition, 
overlooking the detrimental effects on inflammation-induced damage associated to dysbiosis, causing low drug 
tolerability and patient noncompliance.
Here, we have characterized the intestinal injury induced in a dysbacteriosis model by oral administration of 
ceftriaxone24,25, underlying the time-dependent (5 and 15 days) alteration of intestinal homeostasis, the devel-
opment of inflammatory damage and the impact on gut microbiota composition and diversity. Indeed, we have 
shown ceftriaxone-induced intestinal inflammation at 5 d, that was even more marked at 15 d, ten days after 
antibiotic withdrawal. The unbalance of pro- and anti-inflammatory mediators by ceftriaxone has been associated 
to an alteration of occludin transcription in colonic mucosa, indicating an impairment of its integrity25. The dis-
rupted organization of mucosa increased the risk of bacteria endotoxin translocation26, confirmed by the increase 
of circulatory pro-inflammatory cytokines, suggesting that intestinal inflammation affected systemic immunity. 
Actually, FBA showed an anti-inflammatory effect even in the early phase of AIJ, reducing colonic expression of 
cytokines, lasting for 15 days, as also evidenced by histological analysis by an improvement of mucosa structure 
characterized by regular brush border and crypts and reduced presence of apoptotic bodies.
TJ proteins contribute to the primary physical barrier in intestine and the loss of their expression is associated 
to several inflammatory bowel diseases27. We have recently demonstrated that FBA, as well as sodium butyrate, 
restored gut integrity in mice with dextran sulfate sodium–induced colitis20. Consistently, in ceftriaxone-induced 
damage, FBA treatment restored the transcription of OCLN, counteracting the leaky gut, and increased AQP9 
expression involved in the restoration of water and solute homeostasis22. Previous findings clearly indicated the 
involvement of AQP9 in the synthesis and secretion of mucus, which protects the intestinal surface and improves 
the flow of the intestinal content28. Indeed, apart from a restoration of mucus thickness, shown by histological 
analysis at 15d, FBA was able to modulate, already at 5-day treatment, MUC2 expression, whose increase together 
with that of TFF3, strengthened the reparative effect of FBA. The altered intestinal integrity leads to translocation 
of PAMPs and DAMPs into the liver, triggering a vicious loop between gut and liver and contributing to systemic 
inflammation29. Indeed, ceftriaxone not only increased TLR4/MyD88 pattern in the colon, but also in the liver, 
where NLRP3 appeared up-regulated, suggesting the activation of innate immune response and hence inflamma-
tion. FBA prevented immune response activation, both in colon and liver, damping inflammasome upregulation 
and NFκB activation. This latter event in turn induces the expression of pro-inflammatory cytokines, that initial-
ize Th1 cells and promote a vicious self-feeding cycle. While TLR4 senses lipopolysaccharide from gram-negative, 
initiating its signaling, TLR2 recognizes gram-positive bacteria, indicating TLR2 and TLR4 role in intestinal 
homeostasis. Notably, colonic TLR2 appeared down-regulated in AIJ mice, an expression profile that was already 
shown by Grasa et al.30 7 days after antibiotic treatment of mice. This data suggested an alteration at colonic level 
in the recognition of gram-positive and -negative bacteria after antibiotic administration, a pathological altera-
tion partially reverted by FBA treatment.
The protective effect of FBA was confirmed by the decrease in serum AST and ALT, highlighting that the 
reduction of intestinal inflammation can reduce liver alteration and normalize immune tolerance. These data are 
consistent with our previous studies on FBA anti-inflammatory effect both in gastrointestinal and extra-intestinal 
disorders13,14,21.
Furthermore, by deep sequencing approach, we evaluated the modulation of gut microbiota composition upon 
oral administration of ceftriaxone and FBA. Antibiotic treatment induced severe modifications of gut micro-
biota, including: strong depletion of bacterial richness, marked increase of Proteobacteria and Cyanobacteria 
generally represented at low levels in healthy gut, and reduction of Bacteroidetes and Firmicutes phyla, includ-
ing butyrate-producing bacteria. The detriment of butyrate-producing bacteria may impact gut homeostasis, 
since butyrate is the major source of energy for colonocytes, defending the host from inflammation and cell 
apoptosis31. The main altered microbial taxa were mostly restored to early values at 15 days, ten days after anti-
biotic withdrawal, indicating a trend toward reestablishing typical balance of gut microbiota. Fifteen days of 
FBA treatment in AIJ mice powerfully increased colonization of Firmicutes, and specifically of Enterococcus (E. 
faecium and U.s. of Enterococcus) and Clostridium (C. butyricum and C. quinii) genera. C. butyricum is a probiotic 
strain promoting the proliferation of beneficial bacteria, such as Lactobacillus and Bifidobacterium in intestinal 
disorders treatment32. Ling et al.24, in a model of antibiotic-associated diarrhea induced by ceftriaxone admin-
istration, have shown that a mixture of C. butyricum and B. infantis induces beneficial effects on the restoration 
of the intestinal microbiota and the recovery of the tissue architecture. Studies revealed the role of Enterococcus 
spp., Lactobacillales order, in human health as conflicting; Enterococcus may be an opportunistic pathogen under 
certain circumstances, as reported for colorectal cancer patients, and an early colonizer of gut microbiota in phys-
iological condition exhibiting probiotic properties33,34.
FBA administration markedly influenced gut microbiota composition and potentially its functions. 
Correlation analysis showed a marked positive association between key species and specific enzymes, namely 
butyrate producers (C. butyricum, C. quinii) and lactate producers (E. faecium) with butyryl-CoA:acetate 
CoA-transferase and L-lactate dehydrogenase KEGG functions. Our results suggest that FBA treatment positively 
modulates metabolic pathways aimed to enhance lactate and butyrate production and select definite Enterococcus 
and Clostridium species that can operate metabolic cross-feeding.
Many butyrate effects are mainly mediated by two mechanisms: the epigenetic modulation by direct HDAC 
inhibition, causing hyperacetylation of histones35 or/and the direct interaction with its receptors, GPR41 and 
GPR4336. As previously demonstrated, butyrate upregulates the histone H3 acetylation of Foxp3 and promotes the 
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differentiation of Treg, that may contribute to its anti-inflammatory activity37. Furthermore, HDAC9 normally 
suppresses Treg activation, therefore HDAC9 modulation, regulating the expression of heat shock protein 70 and 
controlling Foxp3, may be considered a new therapeutic target to limit colonic inflammation38. Consistently, in 
our experimental condition, FBA inhibited HDAC9 and induced the H3 acetylation.
Here, we also demonstrated that FBA induced the expression of butyrate receptor, GPR43. Indeed, several 
data indicated that SCFAs, including butyrate, directly and indirectly regulate colonic T cells differentiation, 
activating GPR4339. Downregulation of MCT1 expression and/or activity has been evidenced in inflammation of 
colonic mucosa40, colon cancer41, and in response to enteric infection and diarrhea caused by enteropathogenic 
E. coli42. Moreover, IFNγ and TNF-α signaling down-regulates MCT1 expression during inflammation, leading 
to butyrate deficiency in intestinal epithelial cells43. On the other hand, our and other studies showed an upreg-
ulation of MCT1 expression by colon tissues in response to butyrate administration20,44. Here, FBA induced the 
transcription of butyrate transporter, increasing cellular butyrate availability and thus possibly contributing to the 
recover the intestinal inflammatory damage induced by ceftriaxone.
All these data evidence that FBA carried out its pharmacological activity through multiple mechanisms, 
converging on inflammation control and resolution and modulation of microbiota composition, supporting its 
potential in AIJ.
Material and Methods
Animals and Experimental Design. The intestinal dysbiosis was induced in C57Bl/6 male mice 
(10-weeks-old, 25 ± 2 g, Harlan-Corezzano, Italy) by oral administration of ceftriaxone sodium (8 g∙kg−1 dis-
solved in water, Rocephin, Roche S.p.A., Milan, Italy) once daily for 5 days. Antibiotic-treated mice (AIJ) were 
treated simultaneously with FBA (212,5 mg∙kg−1 per die, dissolved in water, per os, once daily) for 5 days or until 
15th day, in order to evaluate its time-dependent effect.
Mice were randomly divided into the following five groups (n = 10, each group): 1) control (CON) mice 
receiving water by gavage as vehicle; 2) mice receiving ceftriaxone for five days (AIJ 5); 3) AIJ 5 mice receiving 
at same time FBA (AIJ 5 + FBA); 4) mice receiving ceftriaxone for five days and sacrificed at day 15 (AIJ 15); 5) 
AIJ 15 mice receiving FBA for 15 days (AIJ 15 + FBA). All procedures involving animals and their care were 
conducted in conformity with international and national law and policies (EU Directive 2010/63/EU for animal 
experiments, ARRIVE guidelines and the Basel declaration including the 3 R concept). The reported procedures 
were approved by the Institutional Committee on the Ethics of Animal Experiments (CSV) of the University of 
Naples Federico II and by the Ministero della Salute under protocol no. 886/2015-PR. As suggested by the animal 
welfare protocol, all efforts were made to minimize animal suffering, reducing the number of animals necessary 
to produce reliable scientific data.
RNA extraction and Real-time semi-quantitative PCR. Mice colons were dissected at 5th and 15th 
day of the experimental period. After wash with PBS to remove the presence of feces, colons were immediately 
frozen in liquid nitrogen. Total RNA was extracted using TRIzol Reagent (Bio-Rad Laboratories) and following 
a specific RNA extraction kit (NucleoSpin®, MACHEREY-NAGEL GmbH & Co, Düren, Germany), according 
to the manufacturer’s instructions. cDna was synthesized using High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) from 4 µg total RNA. The applied PCR settings were previously described45. The used gene 
primers were: Il1b (for IL-1β), Il6 (for IL-6), Tnfa (for TNF-α), Prostaglandin-endoperoxide synthase (Ptgs) 2 (for 
COX-2), Ifng (for IFN-γ), AnxA1 (for Annexin A1), Il10 (for IL-10), Tff3 (for TFF3), Muc2 (for mucin 2), Ocln 
(for Occludin), Tlr2 (for TLR2), MyD88 (for MYD88), Hdac9 (for HDAC9), Slc16a1 (for MCT1) and Nlrp3 (for 
NALP3) (Qiagen, Hilden, Germany) in a final volume of 25 μl. All studied mRNAs were normalized to Gapdh (for 
GAPDH) or Actb (for β-actin) as housekeeping gene, and data were analyzed according to the 2−ΔΔCT method.
Histologic analysis of the colon. At 15 d, colon tissues were collected and stored in formalin 10%. 
Hematoxylin and eosin staining (H&E) was performed and colon sections were analyzed by the same pathologist 
in a blinded manner to evaluate their structure and architecture. Histopathology was quantified based on the 
scoring system indicating mucus thickness and the presence of apoptotic bodies for each animal. Morphological 
changes were evaluated in comparison with CON section.
Western Blot analysis. Colon and liver tissues were homogenized and total protein lysates were subjected 
to SDS-PAGE. To evaluate NFκB activation and histone H3 acetylation, NFκB p65 (Cell Signaling Technology), 
Acetyl-H3 and H3 (EMD Millipore), and IκBα were measured in nuclear and cytosolic extracts, respectively, 
as previously described46. Blots were probed with anti-aquaporin (AQP) 9 (Biorbyt), GPR43 (EMD Millipore), 
TRL4 (Santa Cruz Biotechnology). Western blot for lamin-A, β-Actin and GAPDH (Sigma-Aldrich) was per-
formed to ensure equal sample loading in nuclear and total lysates, respectively.
Microbiota sequencing and data analysis. A subset of mice from each group was analyzed for gut 
microbiota. Fecal microbiota of control (CON) mice treated with vehicle for 5 or 15 days (CON 5 and CON 15, 
respectively) and of AIJ 5, AIJ 5 + FBA, AIJ 15, AIJ 15 + FBA groups was analyzed. Mice were housed in the same 
room, 2 per cage, sorted by treatment and were from different litters. Bacterial genomic DNA was extracted from 
frozen fecal samples using the QIAamp DNA Stool Mini Kit (Qiagen) according to manufacturer’s instructions. 
The quantity and quality of DNA was determined by spectrophotometric measurements (NanoDrop; Thermo 
Fisher Scientific Inc., Waltham, MA, USA). The V3-V4 region of the 16 S rRNA gene from each DNA sample 
was amplified and prepared for sequencing according to the protocol 16 S Metagenomic Sequencing Library 
Preparation for Illumina Miseq System. Barcoded amplicons were mixed in equal amounts based on concen-
trations as determined by Qubit Fluorometer (Invitrogen; Thermo Fisher Scientific, Inc.) and library sizes as 
assessed using a Bioanalyzer DNA 1000 chip (Agilent Technologies Gmbh, Waldbronn, Germany). Normalized 
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libraries (4 nM) were pooled, denatured, diluted to 10 pM and combined with 25% (v/v) denatured 10 pM PhiX 
(Illumina, Inc.), according to Illumina guidelines. Sequencing run was performed on the Illumina MiSeq system 
using v3 reagents for 2 × 281 cycles (Illumina, Inc.).
V3-V4 16 S rDNA FASTQ paired-end reads were pre-processed with PEAR in order to retain high quality 
sequences with an overlap of at least 40 nucleotides, length comprised between 400 and 500 bp and with a PHRED 
score ≥ 33. These reads were then processed with PRINSEQ to obtain FASTA and QUAL files for further analyses. 
Pick of operational taxonomic units (OTUs), taxonomic assignment and diversity analyses were conducted using 
Quantitative Insights Into Microbial Ecology (QIIME) (version 1.8.0). A closed reference-based OTU picking 
method was employed to obtain OTUs at 97% sequence similarity from (May 2013 version). The Greengenes 
16S gene database (GG) database was used to taxonomically classify the identified OTUs and to compute their 
distribution across different taxonomic levels. Samples were normalized to 23,422 sequences/sample using a 
sequence rarefaction procedure. Species heterogeneity within each sample was assessed by employing two Alpha 
diversity metrics (the number Observed species and the Shannon entropy) and compared using a two-sample 
permutation t-test, using 999 Monte Carlo permutations to compute p-values. OTUs diversity among microbial 
communities (beta diversity) was assessed by calculating unweighted Unifrac distances and compared by using 
ANOSIM method with 999 permutations. One-way ANOVA followed by Tukey multiple comparison post-hoc 
tests were used to determine statistical differences in OTUs frequencies among groups across different taxonomic 
levels. Species classification was performed using SPecies IdentificatioN of metaGenOmic amplicons program 
(SPINGO) (version 1.3) with default parameters on a representative sequence of each OTU. Metagenomes were 
predicted using PICRUSt based on normalized OTU table, corrected for multiple 16S rRNA gene copy number. 
Kyoto encyclopedia of genes and genomes (KEGG) ortholog abundances of key functions involved in butyrate 
metabolism among groups were compared using one-way ANOVA followed by Tukey multiple comparison 
post-hoc tests. Pearson correlation test was used to assess the eventual association between the amount of key 
bacterial species and KEGG ortholog counts of key functions involved in butyrate metabolism.
Statistical analysis. All shown values were indicated as means ± SEM and statistical significance was set 
at P < 0.05. The statistical analyses were performed with the use of Graph-Pad Prism 7 (Graph-Pad Software, 
La Jolla, CA). For all the experimental data, differences among groups were compared by ANOVA, followed by 
Bonferroni multiple comparison test for multiple comparisons.
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